Zacks: Analysts Expect Aptose Biosciences Inc. (APTO) to Post -$0.17 Earnings Per Share

Share on StockTwits

Wall Street analysts expect Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) to announce earnings of ($0.17) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Aptose Biosciences’ earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.19). Aptose Biosciences posted earnings of ($0.23) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 26.1%. The business is expected to announce its next earnings report on Thursday, May 9th.

According to Zacks, analysts expect that Aptose Biosciences will report full year earnings of ($0.72) per share for the current fiscal year, with EPS estimates ranging from ($0.74) to ($0.69). For the next fiscal year, analysts expect that the firm will post earnings of ($0.82) per share, with EPS estimates ranging from ($0.94) to ($0.72). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Aptose Biosciences.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.01).

Several equities analysts have weighed in on the company. HC Wainwright set a $9.00 price objective on Aptose Biosciences and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Zacks Investment Research cut Aptose Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, March 26th. Royal Bank of Canada assumed coverage on Aptose Biosciences in a research note on Friday, March 1st. They set an “outperform” rating and a $6.00 price objective on the stock. Citigroup assumed coverage on Aptose Biosciences in a research note on Friday, January 25th. They set an “outperform” rating and a $6.00 price objective on the stock. Finally, Oppenheimer assumed coverage on Aptose Biosciences in a research note on Thursday, January 24th. They set an “outperform” rating and a $6.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $5.71.

NASDAQ:APTO traded down $0.02 during trading hours on Friday, hitting $1.83. 103,226 shares of the company traded hands, compared to its average volume of 273,304. Aptose Biosciences has a one year low of $1.57 and a one year high of $4.55. The stock has a market cap of $73.66 million, a PE ratio of -2.13 and a beta of 1.61.

In other Aptose Biosciences news, CFO Gregory K. Chow bought 15,000 shares of the stock in a transaction dated Wednesday, March 13th. The shares were bought at an average cost of $1.75 per share, for a total transaction of $26,250.00. Following the purchase, the chief financial officer now directly owns 122,014 shares of the company’s stock, valued at approximately $213,524.50. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Erich Platzer sold 20,000 shares of Aptose Biosciences stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $2.19, for a total value of $43,800.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have acquired 35,000 shares of company stock worth $63,750.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new stake in shares of Aptose Biosciences during the 1st quarter worth $198,000. Geode Capital Management LLC bought a new stake in shares of Aptose Biosciences during the 4th quarter worth $33,000. Noven Financial Group Inc. bought a new stake in shares of Aptose Biosciences during the 4th quarter worth $27,000. Patriot Financial Group Insurance Agency LLC raised its stake in shares of Aptose Biosciences by 11.4% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 57,429 shares of the biotechnology company’s stock worth $110,000 after purchasing an additional 5,890 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of Aptose Biosciences by 1,130.9% during the 3rd quarter. Renaissance Technologies LLC now owns 183,401 shares of the biotechnology company’s stock worth $477,000 after purchasing an additional 168,501 shares during the period. Institutional investors own 7.68% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Featured Article: How to Calculate Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks Investment Research Lowers Oshkosh  to Hold
Zacks Investment Research Lowers Oshkosh to Hold
NetSol Technologies  Downgraded by TheStreet to C+
NetSol Technologies Downgraded by TheStreet to C+
APA Group  Reaches New 52-Week High at $10.34
APA Group Reaches New 52-Week High at $10.34
Short Interest in Texas Instruments Incorporated  Declines By 14.1%
Short Interest in Texas Instruments Incorporated Declines By 14.1%
Two Rivers Bancorp  Given Average Rating of “Strong Buy” by Analysts
Two Rivers Bancorp Given Average Rating of “Strong Buy” by Analysts
Cowen Begins Coverage on CarGurus
Cowen Begins Coverage on CarGurus


© 2006-2019 Ticker Report